The
View from Here
Thomas Joos
This month's e-newsletter will provide an update on
biomarkers. The ideal biomarker is specifically associated with a
particular disease or a disease state and should have an expression level
that is predictable... Read
more...
Upcoming
Issues
Issue 3/March'06
Cancer
Therapeutics
Issue
4/April'06
Bioinformatics
Issue
5/May'06
Gene
Expression Profiling
|
|
|
|
Top
Reviews
Using imaging
biomarkers to accelerate drug development and clinical trials
Homer
H. Pien, Alan J. Fischman, James H. Thrall and A. Gregory
Sorensen
Drug Discovery Today
There is increasing evidence that human medical imaging
can help answer key questions that arise during the drug development
process. Imaging modalities such as magnetic resonance imaging,
computed tomography and positron emission tomography can offer
significant insights into the bioactivity, pharmacokinetics and
dosing of drugs, in addition to supporting registration
applications...
Molecular biomarkers
in drug development
David A. Lewin and Michael P. Weiner
Drug
Discovery Today
Arguably, the most immediately promising reverberation
of the genomics era has been the application of biomarkers to drug
development. The promise of applying biomarkers to early drug
development is that they might aid in preclinical and early clinical
decisions such as dose ranging, definition of treatment regimen, or
even a preview of efficacy...
Integrating disease
knowledge and technology to deliver protein targets and biomarkers
into drug discovery projects
Thomas
E. Fehniger, Thomas Laurell and György Marko-Varga
Drug
Discovery Today: Technologies
Biomarker discovery is dependent upon two disciplines:
the field of clinical bioanalysis linked to disease aetiology and
the application of high level technology platforms for identifying
proteins/peptides in complex samples...
Click here
to subscribe to to Drug Discovery
Today.
|
|
| |
PharmaDiscovery - An
Elsevier Event
10-12th May 2006, Bethesda, Maryland
Featured
session: Innovation in biomarker research, development and
application
CHAIR:
Ewoud-Jan-van Hoogdalem, CMO, Octoplus, NL
Click here to
download the conference brochure and/or
register.
|
| |
Abstracts
of Key Research Papers
Multiplex proteomic approaches to sepsis research: case
studies employing new technologies
J.
G. Heuer, D. J. Cummins and B. T. Edmonds
Expert
Rev Proteomics. 2005 Oct;2(5):669-80.
Candidate-based
proteomics in the search for biomarkers of cardiovascular disease
L.
Anderson
J
Physiol. 2005 Feb 15;563(Pt 1):23-60.
Perspective: a program to improve protein biomarker
discovery for cancer
R.
Aebersold, L. Anderson, R. Caprioli, B. Druker, L. Hartwell and R.
Smith
J
Proteome Res. 2005 Jul-Aug;4(4):1104-9.
A human protein atlas for normal and cancer tissues based
on antibody proteomics
M.
Uhlen, E. Bjorling et al.
Mol
Cell Proteomics. 2005 Dec;4(12):1920-32.
A cell proliferation signature is a marker of extremely
poor outcome in a subpopulation of breast cancer
patients
H.
Dai, L. van't Veer et al.
Cancer
Res. 2005 May 15;65(10):4059-66.
Mass spectrometry as a diagnostic and a cancer biomarker
discovery tool: opportunities and potential limitations
E.
P. Diamandis
Mol
Cell Proteomics. 2004 Apr;3(4):367-78.
Analysis of serum proteomic patterns for early cancer
diagnosis: drawing attention to potential problems
E.
P. Diamandis
J
Natl Cancer Inst. 2004 Mar
3;96(5):353-6.
| |
RELATED
CONFERENCES
PharmaDiscovery
2006
Cancer
Biomarker Development
SCIpharm
2006
RELATED
JOBS
Assay
Specialist - Clinical
Pfizer, Groton, Connecticut
[more
details]
Faculty
Positions in Neuroscience
University of Chicago
[more
details]
Research
Fellows/Senior Research Fellows
UHI Millennium
Institute
[more
details]
|
|
